康乐卫士（833575）9月17日大宗交易平台出现一笔成交，成交量100.00万股，成交金额1618.00万元， 大宗交易成交价为16.18元，相对今日收盘价折价2.18%。该笔交易的买方营业部为中信证券股份有限公 司北京呼家楼证券营业部，卖方营业部为中信证券华南股份有限公司昆明青年路证券营业部。 注：本文系新闻报道，不构成投资建议，股市有风险，投资需谨慎。 （文章来源：证券时报网） 证券时报·数据宝统计显示，康乐卫士今日收盘价为16.54元，下跌1.61%，日换手率为1.16%，成交额为 3625.17万元，近5日该股累计上涨0.36%。 9月17日康乐卫士大宗交易一览 | 成交量 | 成交金额 | 成交价格 | 相对当日收 盘价折溢价 | 买方营业部 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | | （万股） | （万元） | （元） | | | | | | | | （%） | | | | 100.00 | 1618.00 | 16.18 | -2.18 | 中信证券股份有限公司 | 中信证券华南股份有限公 | | | | | | 北京呼家楼证券营业部 | ...

每经讯，2025年9月17日，北交所上市公司康乐卫士（833575，收盘价：16.54元）发生一笔大宗交易，成交价16.18元/股，成交 数量100万股，成交金额1618万元，折价2.18%。买入营业部是中信证券股份有限公司北京呼家楼证券营业部，卖出营业部是中 信证券华南股份有限公司昆明青年路证券营业部。 （记者 张喜威） 免责声明：本文内容与数据仅供参考，不构成投资建议，使用前核实。据此操作，风险自担。 每日经济新闻 ...

Core Viewpoint - The announcement of HPV vaccines being included in the national immunization program is expected to positively impact the HPV vaccine market and related companies, which have been struggling with declining performance [1][3][4]. Group 1: Market Response - On September 11, HPV vaccine concept stocks in the A-share market saw a rise, with notable increases in companies such as Kangla Weishi (up 3.09%), Wantai Biological Pharmacy (up 2.69%), Zhifei Biological Products (up 1.98%), and Watson Bio (up 1.71%) [1]. - The National Health Commission's announcement regarding the introduction of HPV vaccination services for eligible girls and its inclusion in the national immunization plan is a significant development [1][2]. Group 2: Industry Challenges - HPV vaccine manufacturers are currently facing challenges due to declining sales and increased competition in the market, leading to a price war [3][4]. - The performance of HPV vaccine companies has been poor, with Wantai Biological reporting a revenue of 844 million yuan, down 38.25% year-on-year, and a net loss of 144 million yuan [4]. - Watson Bio's revenue was 1.154 billion yuan, down 19.47%, with a net profit decline of 74.69% [4]. - Zhifei Biological reported a revenue of 4.919 billion yuan, down 73.06%, and a net loss of 597 million yuan, a 126.72% decline [4][5]. Group 3: Potential for Growth - The global incidence of cervical cancer is rising, particularly among younger women in China, highlighting the need for effective HPV vaccination [6]. - The World Health Organization recommends that countries include HPV vaccination in their national immunization programs, prioritizing girls aged 9 to 14 [6]. - Currently, 143 out of 194 WHO member countries have included HPV vaccines in their national immunization plans, indicating a global trend towards increased vaccination [6]. - With the supply of HPV vaccines becoming sufficient and prices decreasing, the timing for including HPV vaccines in the national immunization program in China is considered ripe [7]. - The minimum price for HPV vaccines has dropped to 27.5 yuan per dose, significantly lower than initial prices, making it more accessible [7]. - If included in the national immunization program, HPV vaccines would likely see increased sales despite lower profit margins compared to local immunization programs [7].

Core Viewpoint - The article discusses the recent announcement by the National Health Commission of China to include HPV vaccines in the national immunization program, which is expected to boost the performance of HPV vaccine manufacturers struggling with declining sales and profits [3][4]. Group 1: Market Performance of HPV Vaccine Companies - HPV vaccine stocks in the A-share market saw a rise, with notable increases in companies like Kangla Weishi (3.09%), Wantai Biological (2.69%), Zhifei Biological (1.98%), and Watson Bio (1.71%) [3]. - The HPV vaccine market in China has become increasingly competitive, leading to a price war and a decline in public willingness to get vaccinated, which has negatively impacted sales [6][7]. - For instance, Wantai Biological reported a revenue of 844 million yuan, down 38.25% year-on-year, and a net loss of 144 million yuan [7]. Watson Bio's revenue was 1.154 billion yuan, down 19.47%, with a net profit decline of 74.69% [7]. Zhifei Biological's revenue fell to 4.919 billion yuan, down 73.06%, with a net loss of 597 million yuan [7]. Group 2: HPV Vaccine Market Dynamics - The HPV vaccine market in China has seen a total of six listed vaccines, including three bivalent, one quadrivalent, and two nonavalent vaccines [5][6]. - The initial demand for HPV vaccines was high, but the market has cooled due to increased competition and limited public awareness and financial capability [6]. - The World Health Organization recommends that countries include HPV vaccination in their national immunization programs, prioritizing girls aged 9 to 14 [9]. As of the end of 2024, 143 out of 194 WHO member countries have included HPV vaccines in their national programs [9]. Group 3: Future Prospects of HPV Vaccines in China - The inclusion of HPV vaccines in the national immunization program is seen as timely due to sufficient supply and decreasing prices, with the lowest bid for HPV vaccines currently at 27.5 yuan per dose [11]. - Industry insiders suggest that the bivalent HPV vaccine is likely to be included in the national immunization program, which would stabilize prices and increase sales volume [11]. - Although profit margins may be lower under the national program, they could still be higher than those under local immunization programs, where competition is more intense [11].

Core Viewpoint - HPV vaccine manufacturers are currently facing performance declines, but the recent inclusion of HPV vaccines in the national immunization program may provide a potential boost to the industry [1][2]. Industry Overview - There are currently six HPV vaccines listed in China, including three bivalent, one quadrivalent, and two nonavalent vaccines [2]. - The HPV vaccination market in China has become competitive, with initial high demand now facing challenges due to increased competition, low public awareness, and limited payment capabilities [2]. Company Performance - WanTai Bio achieved revenue of 844 million yuan in the first half of the year, a year-on-year decline of 38.25%, with a net loss of 144 million yuan [3]. - Watson Bio reported revenue of 1.154 billion yuan, down 19.47%, and a net profit of 43.16 million yuan, down 74.69% [3]. - Zhifei Biological's revenue was 4.919 billion yuan, a decrease of 73.06%, with a net loss of 597 million yuan, reflecting a decline of 126.72% [3][4]. - Companies are facing challenges in sales, leading to asset impairment provisions, including a 76.3 million yuan impairment for bivalent HPV vaccine intangible assets by Watson Bio [3]. Market Demand and Health Impact - Cervical cancer is the fourth most common malignancy among women globally, with significant incidence and mortality rates in China, particularly among younger women [5]. - The World Health Organization recommends that countries include HPV vaccination in their national immunization programs, prioritizing girls aged 9 to 14 [5][6]. National Immunization Program Inclusion - As of the end of 2024, 143 out of 194 WHO member countries have included HPV vaccines in their national immunization programs, but China has not yet done so [6]. - Several regions in China are already offering free HPV vaccinations for eligible girls, indicating a growing trend towards public health initiatives [7]. - The current lowest price for HPV vaccines is 27.5 yuan per dose, significantly lower than initial prices, making it more accessible [7]. - If included in the national immunization program, bivalent HPV vaccines are expected to see increased sales, although profit margins may be lower compared to local immunization programs [7].

中信证券股份有限公司 关于北京康乐卫士生物技术股份有限公司 2025年半年度持续督导跟踪报告 根据《证券发行上市保荐业务管理办法》《北京证券交易所股票上市规则》等 有关法律法规、规范性文件等的规定，中信证券股份有限公司（简称"中信证券"） 作为北京康乐卫士生物技术股份有限公司(以下简称"康乐卫士""上市公司""公 司"）的保荐人，负责康乐卫士的持续督导工作，并出具 2025 年半年度持续督导跟 踪报告。 一、持续督导工作概述 | 项目 | 工作内容 | | --- | --- | | 1.公司信息披露审阅情况 | 保荐人及时审阅公司信息披露文件 | | | 保荐人查阅公司截至2025年半年度末制定、修订的制度文件，督导公 | | 2.督导公司建立健全并有 | 司建立健全并有效执行公司治理、财务内控和信息披露等制度。根据 | | 效执行规章制度的情况 | 公司 年度内部控制自我评价报告，发行人有效执行了相关规则 2024 | | | 制度。 | | | 保荐人查阅公司募集资金管理相关制度、募集资金使用台账、募集资 | | | 金专户银行对账单，查看募投项目进度，了解募集资金使用情况，对 | | 3.募集资金监督 ...

Core Viewpoint - The recent executive changes at Kang Le Wei Shi (康乐卫士) indicate a significant restructuring within the company, coinciding with its transition from a research-focused pipeline to commercialization in the vaccine industry [1][5]. Executive Changes - On September 4, 2023, Kang Le Wei Shi announced the resignation of COO Hao Chunli and Vice President Yi Chuanchao due to personal reasons, marking a shift in the management structure [1][2]. - Hao Chunli retains his position as a board member, while Yi Chuanchao has completely stepped down from all roles within the company and its subsidiaries [1][2]. Shareholding Information - As of the latest announcement, Hao Chunli holds 3.2514 million shares, representing 1.16% of the company, while Yi Chuanchao holds 900,000 shares, accounting for 0.32% [2]. Financial Performance - For the first half of 2025, Kang Le Wei Shi reported revenue of 0.01 billion yuan, a year-on-year increase of 122.18%, but still recorded a net loss attributable to shareholders of 1.472 billion yuan, indicating a significant gap to break even [2][3]. - The gross profit margin decreased to 49.91% from 95.49% in the same period last year [3]. Management Structure and Strategy - The recent executive changes follow the company's announcement of its half-year report and the establishment of a Chief Marketing Officer position, suggesting a comprehensive restructuring of management and operational focus [2][5]. - The company is currently transitioning from a research pipeline to commercialization, with new executives bringing external experience to enhance product commercialization and operational systems [5]. Market Position - As of September 5, 2023, Kang Le Wei Shi's total market capitalization was 4.734 billion yuan, with stock prices fluctuating around 16 yuan [5].

证券代码：833575 证券简称：康乐卫士 公告编号：2025-091 北京康乐卫士生物技术股份有限公司 高级管理人员离任公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带法律责任。 一、高级管理人员离任的基本情况 本公司郝春利先生，因个人原因辞任，自 2025 年 9 月 4 日起不再担任首席运营官。 该人员持有公司股份 3,251,441 股，占公司股本的 1.16%，不是失信联合惩戒对象，离 任后继续担任董事职务，存在未履行完毕的公开承诺。 本公司仪传超先生，因个人原因辞任，自 2025 年 9 月 4 日起不再担任副总裁。该 人员持有公司股份 900,000 股，占公司股本的 0.32%，不是失信联合惩戒对象，离任后 不再担任公司及其控股子公司其它职务，存在未履行完毕的公开承诺。 郝春利先生、仪传超先生已披露的公开承诺事项均正常履行，不存在超期未履行完 毕及违反承诺的情形，离任后将继续履行相关承诺。 二、合规性说明及影响 （一）人员变动的合规性说明 上述人员离任未导致公司董事会成员人数低于法定最低人数，未 ...

Core Viewpoint - The companies listed on the Beijing Stock Exchange (BSE) demonstrated strong resilience and vitality in their 2025 semi-annual reports, with a significant number achieving substantial revenue and profit growth despite a complex market environment [1][2]. Revenue Performance - A total of 208 companies reported revenues exceeding 100 million yuan, with 17 companies surpassing 1 billion yuan, marking them as the "revenue leaders" of the BSE [2]. - Among these, Better Ray (贝特瑞) led with a revenue of 7.838 billion yuan, a year-on-year increase of 11.36%, and a net profit of 479 million yuan [2]. - Other notable companies in terms of revenue include Yinuowei (一诺威) at 3.550 billion yuan, Tongli Co. (同力股份) at 3.169 billion yuan, and Ying Tai Bio (颖泰生物) at 2.966 billion yuan [2]. Profitability - Out of 223 companies, 82.29% reported positive net profits, indicating a robust profitability landscape [3]. - Seven companies achieved net profits exceeding 100 million yuan, with Better Ray again leading at approximately 479 million yuan, followed by Development Technology (开发科技) at 395 million yuan [3]. - Jinbo Bio (锦波生物) reported a revenue of 859 million yuan, a 42.43% increase year-on-year, and a net profit of 392 million yuan, reflecting a 26.65% growth [3]. Profit Growth - Approximately 50% of companies, or 136 in total, reported year-on-year growth in net profits, with 27 companies doubling their profits [4]. - Shibibai (拾比佰) turned a profit with a net profit of 29.226 million yuan, attributed to increased sales driven by government policies and improved internal management [4]. - Chuangyuan Xinke (创远信科) achieved a revenue of 111 million yuan, a growth of 18.44%, and a net profit of 6.3153 million yuan, marking a significant increase of 354.24% [4]. Dividend Distribution - Over 20 companies announced interim dividend plans, reflecting a commitment to returning value to investors [6]. - Jinbo Bio plans to distribute a cash dividend of 10 yuan per 10 shares, totaling approximately 115 million yuan [6]. - Guoxin Technology (广信科技) proposed its first dividend since listing, with a plan to distribute 6.56 yuan per 10 shares, amounting to around 60 million yuan [6].

Market Overview - The biopharmaceutical sector experienced a decline of 2.85% on August 27, with Kanghua Biotech leading the drop [1] - The Shanghai Composite Index closed at 3800.35, down 1.76%, while the Shenzhen Component Index closed at 12295.07, down 1.43% [1] Individual Stock Performance - Wuwei Biotech (300357) saw a significant increase of 5.38%, closing at 30.95 with a trading volume of 299,000 shares and a transaction value of 915 million yuan [1] - Kanghua Biotech (300841) reported a notable decline of 8.89%, closing at 76.60 with a trading volume of 125,200 shares and a transaction value of 993 million yuan [2] - Anke Biotech (300009) also faced a drop of 5.59%, closing at 11.14 with a trading volume of 862,300 shares and a transaction value of 990 million yuan [2] Capital Flow Analysis - The biopharmaceutical sector experienced a net outflow of 1.853 billion yuan from institutional investors, while retail investors saw a net inflow of 1.543 billion yuan [2] - The capital flow for individual stocks indicates that Hualan Biotech (002007) had a net inflow of 32.28 million yuan from institutional investors, while it faced a net outflow of 40.67 million yuan from speculative funds [3] - The overall trend shows that retail investors are actively investing in the sector despite the institutional outflows [2][3]